Home › RLT targets by cancer › Breast Cancer
Radioligand therapy · Breast Cancer

Radioligand Therapy Targets in Breast Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in breast cancer (including triple-negative (TNBC) and HER2-positive subtypes). 4,449 show detectable protein staining. Established and emerging radioligand targets expressed in breast cancer include HER3 (ERBB3), FAP, STEAP2 and B7-H3 (CD276). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own breast cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank breast cancer targets free

Established and emerging radioligand targets in breast cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in breast cancer:

TargetIHC in breast cancer% positiveInternalizes
HER3 (ERBB3)High (0.91)100%yes
FAPHigh (0.77)90%yes
STEAP2High (0.70)100%—
B7-H3 (CD276)High (0.58)100%—
c-MET (MET)High (0.58)100%yes
HER2 (ERBB2)High (0.52)64%yes
ITGAVMedium (0.50)83%—
TMEFF2Medium (0.44)83%—
EPCAMMedium (0.36)50%—
Nectin-4 (NECTIN4)Medium (0.28)75%no
ITGB6Low (0.19)25%—
SSTR2Low (0.18)55%yes
EGFRLow (0.17)30%yes
Mesothelin (MSLN)Low (0.14)17%yes
CD38Low (0.03)8%—
DLK1Low (0.03)8%—

Top cell-surface targets for breast cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in breast cancer% positiveInternalizesClinical stage
1HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.91)100%yesFDA-Approved
2ESR1
estrogen receptor 1
High (0.70)70%yesFDA-Approved
3IGF1R
insulin like growth factor 1 receptor
High (0.82)100%yesFDA-Approved
4NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.86)100%uncertainFDA-Approved
5CYSLTR2
cysteinyl leukotriene receptor 2
High (0.83)92%yesDiscovery
6c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.58)100%yesFDA-Approved
7FGFR1
fibroblast growth factor receptor 1
High (0.67)100%yesFDA-Approved
8S1PR1
sphingosine-1-phosphate receptor 1
High (0.56)83%yesFDA-Approved
9CHRM2
cholinergic receptor muscarinic 2
High (0.91)100%uncertainFDA-Approved
10AMFR
autocrine motility factor receptor
High (0.93)100%yesDiscovery
11MST1R
macrophage stimulating 1 receptor
High (0.64)100%yesFDA-Approved
12MAOB
monoamine oxidase B
High (0.92)100%—FDA-Approved
13GPR139
G protein-coupled receptor 139
High (0.89)100%yesDiscovery
14HTR2B
5-hydroxytryptamine receptor 2B
High (0.83)92%uncertainFDA-Approved
15IL1R2
interleukin 1 receptor type 2
High (0.67)100%yesDiscovery
16FAAH
fatty acid amide hydrolase
High (0.85)100%—FDA-Approved
17FLT4
fms related receptor tyrosine kinase 4
Medium (0.47)80%yesFDA-Approved
18IRAK4
interleukin 1 receptor associated kinase 4
High (0.69)100%yesClinical
19EDNRB
endothelin receptor type B
High (0.69)100%uncertainFDA-Approved
20NOTCH1
notch receptor 1
High (0.64)100%yesClinical
21HRH4
histamine receptor H4
High (0.67)100%yesClinical
22VIPR1
vasoactive intestinal peptide receptor 1
High (0.61)100%yesDiscovery
23HTR6
5-hydroxytryptamine receptor 6
Medium (0.47)90%yesFDA-Approved
24SCTR
secretin receptor
High (0.92)100%uncertainDiscovery
25LSR
lipolysis stimulated lipoprotein receptor
High (0.79)100%yesDiscovery

Internalizing receptors in breast cancer

Targets expressed in breast cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

HER3 (ERBB3) · ESR1 · IGF1R · CYSLTR2 · c-MET (MET) · FGFR1 · S1PR1 · AMFR · MST1R · GPR139 · IL1R2 · FLT4

Breast Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in breast cancer. Clinical precedent lowers development risk but usually means more competition:

HER3 (ERBB3) · ESR1 · IGF1R · NR3C2 · c-MET (MET) · FGFR1 · S1PR1 · CHRM2 · MST1R · MAOB · HTR2B · FAAH

How these breast cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in breast cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank breast cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free breast cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist breast cancer targets for your program · 5 free analyses, no card Rank breast cancer targets free